| Literature DB >> 35743006 |
Maria C Teixeira1, Nicole S Lameirinhas1, João P F Carvalho1, Armando J D Silvestre1, Carla Vilela1, Carmen S R Freire1.
Abstract
Three-dimensional (3D) bioprinting is an innovative technology in the biomedical field, allowing the fabrication of living constructs through an approach of layer-by-layer deposition of cell-laden inks, the so-called bioinks. An ideal bioink should possess proper mechanical, rheological, chemical, and biological characteristics to ensure high cell viability and the production of tissue constructs with dimensional stability and shape fidelity. Among the several types of bioinks, hydrogels are extremely appealing as they have many similarities with the extracellular matrix, providing a highly hydrated environment for cell proliferation and tunability in terms of mechanical and rheological properties. Hydrogels derived from natural polymers, and polysaccharides, in particular, are an excellent platform to mimic the extracellular matrix, given their low cytotoxicity, high hydrophilicity, and diversity of structures. In fact, polysaccharide-based hydrogels are trendy materials for 3D bioprinting since they are abundant and combine adequate physicochemical and biomimetic features for the development of novel bioinks. Thus, this review portrays the most relevant advances in polysaccharide-based hydrogel bioinks for 3D bioprinting, focusing on the last five years, with emphasis on their properties, advantages, and limitations, considering polysaccharide families classified according to their source, namely from seaweed, higher plants, microbial, and animal (particularly crustaceans) origin.Entities:
Keywords: 3D bioprinting; bioinks; cell-laden constructs; hydrogels; polysaccharides
Mesh:
Substances:
Year: 2022 PMID: 35743006 PMCID: PMC9223682 DOI: 10.3390/ijms23126564
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Most relevant polysaccharides from different sources used as raw materials for the fabrication of hydrogel-based bioinks for 3D bioprinting applications. Image created with BioRender.com.
Summary of the recent studies on seaweed derived polysaccharide-based bioinks for 3D bioprinting applications.
| Polysaccharide | Other Compounds | Cell Type | Bioink Formulation | Bioprinting Method | Conditions | Construct Properties | Application | Ref. |
|---|---|---|---|---|---|---|---|---|
| Alginate | Gelatin | rBMSC | Alginate: 6 wt.% | EB | Nozzle: 0.610 mm | Grid-like scaffolds with 10 × 10 × 5 mm3 | Bone tissue engineering | [ |
| Alginate | Agarose | Primary chondrocytes | Alginate: 0.1 g/mL | EB | Nozzle: 0.260 mm | Grid-like structures 2 × 2 cm2 with 6 layers | Cartilage tissue engineering | [ |
| Alginate | -- | SK-N-BE cells | Alginate: 2% ( | EB | Nozzle: 0.255 mm | Grid-like geometries | – | [ |
| Alginate | -- | RPSCs | Alginate: 2% ( | EB | Nozzle: 0.200 mm | Cubic shape scaffold (10 × 10 × 5 mm3) with 1 mm distance between strands | Nerve tissue engineering | [ |
| Alginate | Silk fibroin | C3A | Alginate: 5% ( | Co-axial EB | Shell Nozzle: 1.070 mm | Grid-like scaffolds with the size of 20 × 20 × 3 mm3 | – | [ |
| Alginate | Gelatin | Fibroblasts | CNTs: 0.5 and 1%( | EB | Modified printer for bioprinting of hollow tubular scaffolds | Circular tubes printed with a 3 mm diameter, an average wall thickness of 0.5 mm and a length of 7–10 cm | Vessels tissue engineering | [ |
| Alginate | Albumen (Egg white) | HUVECs | Alginate: 5% ( | EB | Nozzle: 0.160 mm | Grid structures with 30 × 30 × 1 mm3 and 25 × 25 × 1 mm3 | – | [ |
| Alginate | Albumen (Egg white) | HUVECs | Alginate: 2–3% ( | EB | Nozzle: 0.500 mm | Patches with 12 × 12 mm2 and 8 mm height | Endothelialized tissue engineering | [ |
| Alginate | Collagen type I | hiMPCs | Alginate: 2% ( | EB | Nozzle: 0.455 mm | Printed spherical discs | Blood vessels tissue engineering | [ |
| Alginate | SFMA | NIH-3T3 | Alginate: 3 wt.% | EB | Pressure: 10 to 100 kPa | Grid like scaffolds with the size of 20 × 20 × 3.5 mm3 | – | [ |
| Alginate | Hyaluronic acid | Mel Im | Alginate: 0.5% ( | EB | Nozzle: 0.580 mm | Grids with 1 cm2 with 3 layers and 6 strands each | In vitro and in vivo metastatic melanoma models | [ |
| Alginate | Gelatin | Primary adult dermal fibroblasts | Alginate: 2% ( | EB | Nozzle: 0.410 mm | Three-layered, disc-shaped constructs of 15 mm diameter, about 3 mm height for characterization | Skin tissue engineering | [ |
| Carrageenan | nSi | MC3T3-E1 | Carrageenan: 2.5 wt.% | EB | Nozzle: 0.340 mm | (i) Single fiber in a lattice network and a layered lattice network; (ii) 30-layer cylinder; (iii) nose and ear models. | – | [ |
| Carrageenan | nSi | MC3T3-E1 | Carrageenan: 1% ( | EB | Nozzle: 0.400 mm | (i) Single fiber in a lattice network and a layered lattice network; (ii) 30-layer cylinder; (iii) nose and ear models. | – | [ |
| Carrageenan | Gelatin | C2C12 | Carrageenan: 2% ( | EB | Nozzle: 0.250 mm | Grid-like scaffolds with 25 × 25 mm2 | – | [ |
| Carrageenan | GelMA | C2C12 | Carrageenan: 2% ( | EB | Nozzle: 0.250 mm | Grid-like scaffolds with 25 × 25 mm2, line space: 1.3 mm, and 4 layers | – | [ |
| Carrageenan | Alginate | MSCs | Carrageenan: 1.5% ( | EB | Nozzle: 0.510 mm | Grid-like scaffolds with 25 × 25 mm2, line space: 1.3 mm, and 4 layers | – | [ |
| Carrageenan-MA | GelMA | ADSCs | Crg-MA: 1% ( | EB | Nozzle: 0.210 mm | Grid-like structure with 10 × 10 mm2 and 10 layers in height | Adipose tissue regeneration | [ |
| Carrageenan | nSi | hMSCs | Carrageenan: 1% ( | EB | Nozzle: 0.400 mm | Mandibular models | Bone tissue engineering | [ |
| Agarose | Alginate | Auricular cartilage digested with Collagenase Type 4 cell suspension | Agarose: 2, 3 and 4% ( | EB | Nozzle: 0.160 mm | Constructs printed as single lines (print width = 0.5 mm, length = 30 mm) | Tissue engineering | [ |
| Agarose | NOCC | neuro2A | Agr stock solution: 1% ( | EB | Nozzle: 0.410 mm | Grid-like scaffolds with 20 × 20 × 0.5 mm3 | – | [ |
Abbreviations: ADSCs–Adipose-derived mesenchymal stem cells; Agr–Agarose; Alg–Alginate; C2C12–Mouse myoblasts cells; C3A–Liver cancer cell line; CNTs–Carbon nanotubes; Col–Collagen; Crg–Carrageenan; Crg-MA–Carrageenan methacrylate; DCEL–Diethylaminoelthyl cellulose; EB–Extrusion bioprinting; G’–storage modulus; Gel–Gelatin; GelMA–Gelatin methacrylate; HA–Hyaluronic acid; hiMPCs–Human induced pluripotent stem cell-derived mesodermal progenitor cells; HUVECs–Human umbilical vein endothelial cells; iPSCs–Induced pluripotent stem cells; MC3T3-E1–Mouse preosteoblasts cell line; Mel Im–Malignant melanoma cell line; MSCs–Mesenchymal stem cells; NOOC–N,O-Carboxymethyl chitosan; nSi–Nanosilicates; rBMSC–Bone marrow stem cells; RPSCs–Schwann cells; SF–Silk fibroin; SFMA–Silk fibroin methacrylate; UV–Ultraviolet light.
Figure 2Schematic representations of some approaches used for the manufacturing of bioinks from seaweed derived polysaccharides. (A) Alginate/SFMA bioinks pre-crosslinked with CaCO3 and then photocrosslinked to produce stable printed constructs with high cell viability (Reproduced with permission from [66]. Copyright American Chemical Society, 2021); (B) NICE bioinks composed by carrageenan, nSi, and GelMA to produce printed mandibular models (Reproduced with permission from [74]. Copyright American Chemical Society, 2020); and (C) bioinks combining agarose and NOOC with high printability and cell viability (Reproduced with permission from [79]. Copyright Elsevier, 2021).
Summary of the recent studies on higher plants derived polysaccharide-based bioinks for 3D bioprinting applications.
| Polysaccharide | Other Compounds | Cell Type | Bioink Formulation | Bioprinting Method | Conditions | Construct Properties | Application | Ref. |
|---|---|---|---|---|---|---|---|---|
| CMC | Sodium alginate | Human pancreatic cancer cells (2 × 106 cells/mL) | Alginate: 4% ( | EB | Nozzle: 0.410 mm | Cubic model (10 × 10 × 2 mm3 with 1 mm of filament distance) was printed | – | [ |
| Sodium carboxymethyl cellulose methacrylate | GelMA, AlgMA PEGDA | C2C12 (1 × 107 cells/mL) | GelMA: 1 or 5% ( | EB | Nozzle: 0.200 mm | Cylindrical model (10 mm in diameter) | Muscle tissue engineering | [ |
| Methyl cellulose | Alginate | Bovine primary chondrocytes (5 × 106 cells/g) | Alginate: 3 wt.% | EB | Nozzle: 0.610 mm | Cubic model (9.5 × 9.5 × 1.4 mm3) | – | [ |
| NorCMC and cCMC | N/A | hMSCs, NIH 3T3 and HUVECs (1 × 107 cells/mL) | cCMC: 15% ( | EB | Printing speed: 5–10 mm/s | Grid-like construct (15 × 15 mm2) | – | [ |
| Hydroxyethyl cellulose | Sodium alginate, Gelatin | MCF-7 (107 cells/mL) | Sodium alginate: 1% ( | EB | Printing speed: 5 mm/s | Cylindrical model (9 × 8 mm2); spheroid model and human ear structure | Breast tumor model | [ |
| Hydroxypropyl methyl cellulose-Si | NaF and glycine | hMSCs (1.106 cells/mL) | NaF and/or glycine was added to obtain a final HPMC-Si | EB | Nozzle: 0.210 mm | Grid-like structures | – | [ |
| Hydroxypropyl methyl cellulose methacrylate | Silk fibroin | BMSCs (1 × 106 cells/mL) | Hydroxypropyl methyl cellulose methacrylate: 5 wt.% | EB | Nozzle: 0.160 mm | Ring-like structure (8 mm diameter); cylindrical (8 × 4 mm2) open structure and human ear structure | Cartilage tissue repair | [ |
| NFC | Poly(2-ethyl-2-oxazoline), Sortase A and alginate | hACs (107 cells/mL) | Poly(2-ethyl-2-oxazoline): 5% ( | EB | Nozzle: 0.410 mm | Grid-like structures | Cartilage tissue engineering | [ |
| NFC | Horseradish peroxidase, glucose, and alginate | 10T1/2 (5 × 105 cells/mL) | NFC: 0.5–1.5% ( | EB | Nozzle: 0.210 mm | Lattice structure (20 × 21 mm2) and human nose (12 × 15 mm2) | – | [ |
| NFC | Alginate, CMC | hSF (106 cells/mL) | Alginate: 3 wt.% | EB | Nozzle: 0.250 mm | Cylinder-shaped structure (10 × 0.8 mm2) | In vitro model of the human dermis | [ |
| NFC | Alginate | hMFC (107 cells/mL) | NFC:Alg: 01:00, 20:80, 50:50, 60:40, 70:30, 80:20 and 90:10, with a solid content of 3.5% ( | EB | Nozzle: 0.413 mm | Block (20 × 20 × 3 mm3) | Human meniscus tissue engineering | [ |
| NFC | Alginate and polydopamine nanoparticles | MC3T3-E1 (6 × 103 cells/cm2) | Alginate: 2.1, 1.5 and 0.9% ( | EB | Nozzle: 0.500 mm | Grid structure (20 × 20 mm2) | Bone tissue engineering | [ |
| NFC | Alginate and fibrinogen | C2C12 (25 × 106 cells/mL) | Commercial inks: | EB | Nozzle: 0.250 mm | Lines (length: 20 mm and thickness: 0.35 mm) | Skeletal muscle regeneration | [ |
| CNC | Platelet lysate | hASCs (1 × 106 cells/mL) | Aldehyde CNC: 18 wt.% | EB | Nozzle: 0.210 mm | Square lattice (1 × 1 × 0.25 cm2) | – | [ |
| CNC | Gelatin methacryloyl and hyaluronic acid methacrylate | ATDC5 (1 × 106 cells/mL) | CNC: 1, 5, 10 and 15% ( | EB | Nozzle: 0.200 mm | Cuboid structures (10 × 10 × 1.5 mm3) | – | [ |
| CNC | Chitosan, hydroxyethyl cellulose | MC3T3-E1 (5 × 106 cells/mL) | Chitosan: 3% ( | EB | Nozzle: 0.900 mm | Cylindrical scaffolds (7.5 × 4 mm2) | – | [ |
| CNC | k-carrageenan and methylcellulose | L929 (3 × 105 cells/mL) | k-carrageenan: 0.3 wt.% | EB | Nozzle: 0.200 mm | Grid-like constructs (10 × 10 cm2) | – | [ |
| BC | Alginate and GelMA | RSC96 (15 × 106 cells/mL) | Alginate: 5% ( | EB | Nozzle: 0.160 mm | Cuboid structure (8 × 8 × 2 mm3), cylinder (5 × 4 mm2) | – | [ |
| TEMPO oxidized bacterial NFC | N/A | R1/E (3 × 107 cells/mL) | TEMPO oxidized bacterial NFC: 1% ( | EB | Nozzle: 0.900 mm | Grid-like constructs | – | [ |
| Pectin methacrylate | N/A | Human neonatal dermal fibroblasts (1.5 or 2.5 wt.%) | Pectin methacrylate: 1.5–2.5 wt.% | EB | Nozzle: 0.642 mm | Cuboid structures (8 × 8 × 4.5 mm3 and 17 × 17 × 2.4 mm3) | Dermal tissue engineering | [ |
| Pectin | Pluronic F127 and alginate | MIN6 (1 × 107 cells/mL) | Pectin: 2 wt.% | EB | Nozzle: 0.455 mm | Grid-like structures (8 × 2 mm2) | – | [ |
Abbreviations: 10T1/2–Mouse fibroblasts; Alg–Alginate; AlgMA–Alginate methacrylate; ATDC5-Mouse teratocarcinoma cells; BC–Bacterial cellulose; BMSCs–Bone marrow mesenchymal stem cells; C2C12-Mouse myoblasts cells; cCMC-Carbic (norbornene) functionalized CMC; CMC–Carboxymethyl cellulose, CMCMA–Carboxymethyl cellulose methacrylate; CNC–Cellulose nanocrystals; GelMA–Gelatin methacrylate; hACs–Human auricular chondrocytes; HAMA–Hyaluronic acid methacrylate; hASCs–Human adipose-derived stem cells; hMFC–Human meniscus fibrochondrocytes; hMSCs–Human mesenchymal stromal cells; hSF–Human-derived skin fibroblasts; HPMC–Hydroxypropyl methyl cellulose; HUVECs-Human umbilical vein endothelial cells; L929–Mouse fibroblasts; MC–Methyl cellulose; MC3T3-E1–Pre-osteoblasts; MCF-7–Human breast cancer cell line; MIN6–Mouse insulinoma cells; NIH3T3–Fibroblasts cell line; NFC– Nanofibrillated cellulose; NorCMC–Norbornene CMC; R1/E–Pluripotent mouse embryonic stem cells; PEGDA-Poly(ethylene glycol) diacrylate RSC96–Schwann cells; TEMPO-(2,2,6,6-Tetramethylpiperidin-1-yl)oxyl.
Figure 3Various approaches for the development of bioinks from higher plant-derived polysaccharides. (A) Bioink from hydroxypropyl methylcellulose and silk fibroin for the bioprinting of BMSCs cells (Reproduced with permission from [114]. Copyright American Chemical Society, 2020); and (B) bioink of methacrylated pectin with RGD for 3D bioprinting of hNDFs cells (Reproduced with permission from [119]. Copyright Royal Society of Chemistry, 2018).
Summary of the recent studies on microbial derived polysaccharide-based bioinks for 3D bioprinting applications.
| Polysaccharide | Other Compounds | Cell Type | Bioink Formulation | Bioprinting Method | Conditions | Construct Properties | Application | Ref. |
|---|---|---|---|---|---|---|---|---|
| Dextran | GelMA, succinylated chitosan and dextran aldehyde | hBMSC (1.0 × 106 cells/mL) and | Succinylated chitosan: 8% ( | EB | Nozzle: 0.400 mm | Core/shell structure (12 × 12 × 4 mm3) | Wound healing | [ |
| Xanthan gum | GelMA, alginate and CMC | hMSCS (2.5 × 106 cells/mL) | GelMA: 10% ( | EB | Nozzle: 0.515 mm | Grid-like structures | – | [ |
| Xanthan gum | Collagen type 1 | ECs/hESC-ECs | Xanthan gum: 10% ( | EB | Nozzle: 0.410 mm | Grid-like constructures (10 ×10 × 3 mm3) | – | [ |
| Xanthan gum | Gelatin | Primary human-derived-skin fibroblasts (0.5 × 106 cells/mL) and | Xanthan gum: 0.3, 0.7 1 and 1.2% ( | EB | Nozzle: 0.250 mm | Grid-like constructs (1 cm2) | – | [ |
| Gellan gum | Poly(lactic acid), GelMA | Mesenchymal stromal cells (10 × 106 cells/mL) | Gellan gum: 1% ( | EB | Nozzle: 0.908 mm | Grid-like structures (2.25 mm line spacing) | – | [ |
| Gellan gum modified with RGD | N/A | Primary cortical neurons (1 × 106 cells/mL) | RGD-gellan gum: 1% ( | EB | Nozzle: 0.200 mm | Cylindrical structure | – | [ |
| Gellan gum | PEGDA | BMSCs (2 × 106 cells/mL) | Gellan gum: 0.75 wt.% | EB | Nozzle: 0.515 mm | Rectilinear and honeycomb structures | Intervertebral disc regeneration | [ |
| Gellan gum | PEGDA | BMSCs and MC3T3-E1 (2 × 106 cells/mL) | Gellan gum: 1.0, 1.5, 2.0 wt.% | EB | Nozzle: 0.515 mm | Sharp cone (10 mm in diameter and height), square prism (bottom diameter 10 mm, top diameter 10 mm, height 10 mm) and human scale ear and nose | – | [ |
| Gellan gum | GelMA | C2C12 (4 × 106 cells/mL) | GelMA: 2, 4, 10, 15, 20, 30% ( | EB | Nozzle: 0.410 mm | Grid pattern (9 × 9 × 10 mm3) and tubular structure | Soft tissue engineering | [ |
| Gellan gum | Sodium alginate and thixotropic magnesium phosphate-based gel | MG-63 (1 × 106 cells/mL) | Sodium alginate: 2.5 or 4.0% ( | EB | Nozzle: 0.410 mm | Grid-like constructs (20 × 20 mm3), human mandible, university symbol abbreviation and human nose | Osteochondral repair | [ |
| Gellan gum | Fibrinogen | pMCs (1.5 × 107 cells/mL) | Gellan gum: 12 mg/mL | EB | Nozzle: 0.240 mm | Cuboid structures (10 × 10 × 5 mm3) | Fibrocartilaginous tissue regeneration | [ |
| Gellan gum | Alginate and laminin | hiNPCs | Two different alginate-gellan gum blends were prepared: 1.5% ( | EB | Nozzle: 0.200 mm | Grid-like structures | In vitro neural models | [ |
Abbreviations: BMSCs–Bone marrow mesenchymal stem cells; C2C12–Mouse myoblasts cells; CMC–Carboxymethyl cellulose; ECs/hESC-ECs–Human embryonic stem cells and endothelial cells; GelMA–Gelatin methacrylate; HaCaTs–Human epidermal keratinocyte; hBMSCs–Human bone marrow derived mesenchymal stem cells; hINPC-hMSCs–Human mesenchymal stromal cells; HUVECS–Human umbilical vein endothelial cells; hINPC–Human induced pluripotent stem cells-derived neural progenitor cells; MC3T2-E1–Pre-osteoblasts; MG-63–Osteosarcoma cells; pMCs–Porcine primary meniscus cells.
Figure 4Diverse strategies for the creation of novel bioinks from microbial derived polysaccharides. (A) Core/shell bioinks composed of dextran aldehyde and succinylated chitosan (core), and GelMA (shell) for the bioprinting of MSCs and HUVECs cells (Reproduced with permission from [151]. Copyright American Chemical Society, 2020); (B) UV-crosslinked bioinks gellan gum and PEGDA with BMSCs and MC3T3-E1 cells (Reproduced with permission from [159]. Copyright Elsevier, 2018).
Summary of recent works on chitosan-based bioinks for 3D bioprinting applications.
| Polysaccharide | Other Compounds | Cell Type | Bioink Formulation | Bioprinting Method | Conditions | Construct Properties | Application | Ref. |
|---|---|---|---|---|---|---|---|---|
| Chitosan | D-(+)-raffinose pentahydrate | Primary human skin fibroblasts | Chitosan: 6% ( | EB | Nozzle: 0.260 mm | Grid structure with 1.6 × 1.6 cm2 | – | [ |
| Chitosan | - | PDLSCs | Chitosan: 1.67% ( | EB | N/A | Lattice-type structure (thickness of 2 mm × 8-layer height) | – | [ |
| Chitosan methacrylate | LAP | HUVECs | Chitosan: 1% ( | EB/DLP | DLP photocuring conditions: | Lattice structure with 10 × 10 × 1 mm3 | Tissue engineering | [ |
| Carboxymethyl chitosan | Oxidized and non-oxidized hyaluronic acid | L929 | Carboxymethyl chitosan: 2 wt.% | EB | Nozzle: 0.200 mm | 2- and 4-layered grid square scaffolds | – | [ |
| Chitosan | Gelatin | U87 | Chitosan/Gelatin/PEG-Star-ma ratio = 1:3:0.05% ( | EB | Nozzle: 0.410 mm | Grid-like structure | In vitro models | [ |
| Chitosan | PEG, α-cyclodextrin and gelatin | MSCs | CS-PEG at 30 mg.mL. Crosslinker: | EB | Nozzle: 0.300–0.400 mm | 3D columnar structures | – | [ |
| Chitosan | Gamma-PGA | Human adult fibroblasts | Chitosan: 4.5% and 6% ( | EB | Nozzle: 0.700 mm (CS) | Rectangular grid structure with 20 × 10 × 1.2 mm3 | – | [ |
| Chitosan methacrylate | β-glycerol phosphate salt | NIH 3T3 | Chitosan: 1.5% ( | EB | Nozzle: 0.720, 0.510 and 0.410 mm | Grid-like structure | – | [ |
Abbreviations: CS–Chitosan; CSMA–Chitosan methacrylate; DLP–Digital light processing; EB–Extrusion bioprinting; L929–Mouse fibroblasts cell line; Gamma-PGA–Poly-gamma-glutamic acid: LAP–Lithium phenyl-2,4,6-trimethylbenzoylphosphinate; MSCs–Mesenchymal stem cells; NIH 3T3–Mouse fibroblasts cell line; PDLSCs–Periodontal ligament stem cells; PEG–poly(ethylene glycol); PEG-Star-ma–Poly(ethylene glycol)-Star-maleimide; HUVECs–Human umbilical vein endothelial cells; U87–Malignant glioma cell line; UV–Ultraviolet light.
Figure 5Different approaches for the development of chitosan-based bioinks. (A) Example of the modification of chitosan (and gelatin) with 5-methyl furfural and crosslinking with Star-PEG-MA for the development of a bioink for 3D bioprinting with U87 cells (Reproduced with permission from [194]. Copyright Frontiers, 2020); (B) dual-crosslinked hydrogel bioink using chitosan methacrylate together with β-glycerol phosphate with NIH 3T3 cells (Reproduced with permission from [197]. Copyright Elsevier, 2020); and (C) bioink based on chitosan, together with β-glycerol phosphate and hydroxyethyl cellulose, reinforced with cellulose nanocrystals, with good printability and high cell viability(Reproduced with permission from [105]. Copyright American Chemical Society, 2021).
Figure 6Some strategies applied for the development of hyaluronic acid-based bioinks. (A) Bioink of hyaluronic acid and alginate for the bioprinting of NIH 3T3 cells. (Reproduced with permission from [203]. Copyright MDPI, 2021); and (B) bioink based on thiol-modified hyaluronic acid and a growth factor (TGF-β1) for the bioprinting of MSCs for chondrogenic differentiation (Reproduced with permission from [205,206]. Copyright John Wiley & Sons, Inc. and MDPI, 2022).